Fortress Biotech, Inc.

NASDAQ:FBIO

Biotechnology

Healthcare
$1.89 -1.79%

-$0.06 today

Market cap
$63.03M
Beta
1.23
P/E (TTM)
0.7
EPS (TTM)
$4.05
52W Low $1.70High $4.53

Volume 0.41M

Average 0.43M

FBIO Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Fortress Biotech, Inc.NASDAQ: FBIO

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization grows, but more slowly than its trailing trend

Q1 FY2026 depreciation & amortization of $1.7M rose 1.4% year over year, behind the +4.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 46.8% from the prior quarter. Over 3 fiscal years it compounded at -20.7% a year.

Context

  • Depreciation & amortization amounted to 7.4% of revenue in FY2025, down 0.4 pp from a year earlier.
  • Depreciation & amortization increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +1.4% toward the trailing-twelve-month pace of +4.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.7M+46.8% QoQ
Last fiscal yearDec 2025
$4.66M+4.4% YoY
LTMMar 2026
$5.17M+4.4% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.4%——
1 year+4.4%——
3-year CAGR-20.7%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
4.66M USD
Year-over-year change
+4.4%
4-year CAGR
-9.0%

Depreciation & Amortization vs competitors

How FBIO compares with its peers on the latest reported figures

  • FBIO's LTM Mar 2026 depreciation & amortization of $5.17M is the 2nd largest of the 10 companies compared; the peer median is $170.49K.
  • Its year-over-year change of +4.4% is the 3rd highest of 8, against a peer median of -13.3%.
  • Depreciation & amortization amounts to 7.8% of revenue for FBIO, versus a peer median of 20.5%.
FBIO Competitors Peer median
Depreciation & Amortization for FBIO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VXRTVaxart, Inc.LTM Mar 2026$7.74M -13.3%+13.9%3.0%
FBIOFortress Biotech, Inc.LTM Mar 2026$5.17M +4.4%-20.7%7.8%
TCRXTScan Therapeutics, Inc.LTM Mar 2026$2.88M -18.4%-17.7%31.5%
XBITXBiotech Inc.LTM Mar 2026$1.58M -10.2%-13.6%—
ADAGAdagene Inc.LTM Jun 2024$515.94K —-25.9%63.2%
NTRBNutriband Inc.LTM Apr 2026$170.49K -37.6%-19.3%9.5%
IMUXImmunic, Inc.LTM Mar 2026$158K +4.6%+29.7%—
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026$131K -84.0%-41.1%—
GANXGain Therapeutics, Inc.LTM Mar 2026$94.69K +12.5%+13.6%—
RLMDRelmada Therapeutics, Inc.LTM Mar 2026$0 ———
Peer median (excluding FBIO) $170.49K-13.3%-15.6%20.5%

Competitors are the stored peer set for FBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(164.83M)(213.91M)(154.15M)(120.86M)(32.92M)
Depreciation & Amortization6.79M9.35M6M4.46M4.66M
Deferred Income Tax00000
Stock-Based Compensation19.49M22.99M17.03M32.62M28.74M
Change in Working Capital36.37M(715K)(12.52M)(8.13M)(25.1M)
Accounts Receivables834K(4.84M)12.52M4.47M(19.33M)
Inventory(8.46M)1.74M3.95M(4.23M)4.81M
Accounts Payables43.31M8.35M(24.38M)(6.39M)(7.97M)
Other Working Capital690K(5.97M)(4.61M)(1.98M)(2.6M)
Other Non-Cash Items(14.36M)2.89M15.42M11.71M(41.17M)
Operating Cash Flow(116.54M)(179.4M)(128.23M)(80.19M)(65.78M)
Capital Expenditures(16.35M)(3.06M)(8.1M)(15M)0
Acquisitions (Net)56.86M(20M)008.96M
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities(11.78M)(213K)(2.04M)01.17M
Investing Cash Flow40.51M(22.93M)(2.1M)(15M)10.12M
Debt Repayment(9.64M)49.25M(38.79M)(7.33M)(5.64M)
Common Stock Issued155.26M40.26M80.38M82.84M84.63M
Common Stock Repurchased0(1.11M)00(265K)
Dividends Paid(8.78M)(8.78M)(8.77M)(4.71M)(664K)
Other Financing Activities(4.8M)(6.74M)(529K)(163K)(360K)
Financing Cash Flow148.99M75.32M32.74M70.64M77.44M
Effect of Forex Changes00000
Net Change in Cash72.97M(127.01M)(97.59M)(24.55M)21.79M
Free Cash Flow(132.89M)(182.46M)(136.32M)(95.19M)(65.78M)

Fortress Biotech, Inc.

NASDAQ:FBIO

Intrinsic Alpha fair value

Locked

Current Price

$1.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.